Transaction DateRecipientSharesTypePriceValue
20th November 2020Group Holdings (Sbs) Advisors, Inc. Tpg29,197Open or private sale$30.38$887,045.74
20th November 2020Scott D Sandell69,564Open or private sale$67.27$4,679,507.67
20th November 2020Group Holdings (Sbs) Advisors, Inc. Tpg6,184Open or private sale$29.75$183,988.22
20th November 2020Scott D Sandell97Open or private sale$65.64$6,367.08
19th November 2020Group Holdings (Sbs) Advisors, Inc. Tpg35,598Open or private sale$29.12$1,036,766.83
19th November 2020Scott D Sandell267,743Open or private sale$65.84$17,626,913.95
19th November 2020Group Holdings (Sbs) Advisors, Inc. Tpg15,051Open or private sale$28.75$432,704.21
18th November 2020Group Holdings (Sbs) Advisors, Inc. Tpg7,383Open or private sale$29.66$218,996.02
18th November 2020Scott D Sandell51,428Open or private sale$65.53$3,369,871.13
18th November 2020Group Holdings (Sbs) Advisors, Inc. Tpg29,137Open or private sale$29.19$850,509.03
Trevi Therapeutics
Trevi Therapeutics logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 9/10.


Trevi Therapeutics, Inc. is a clinical stage biopharmaceutical company. It focuses on the formulation of nalbuphine ER, which use to treat chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia in Parkinson's disease.


Ticker: TRVI
Sector: Healthcare
Industry: Biotechnology
SEC Central Index Key (CIK): 1563880
Employees: 15
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags
Fundamentals